title: Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.
abstract: Genotypic HIV drug resistance testing is routinely used to guide clinical decisions. While genotyping methods can be standardized, a slow, labor-intensive, and subjective manual sequence interpretation step is required. We therefore performed external validation of our custom software RECall, a fully automated sequence analysis pipeline. HIV-1 drug resistance genotyping was performed on 981 clinical samples at the Stanford Diagnostic Virology Laboratory. Sequencing trace files were first interpreted manually by a laboratory technician and subsequently reanalyzed by RECall, without intervention. The relative performances of the two methods were assessed by determination of the concordance of nucleotide base calls, identification of key resistance-associated substitutions, and HIV drug resistance susceptibility scoring by the Stanford Sierra algorithm. RECall is freely available at http://pssm.cfenet.ubc.ca. In total, 875 of 981 sequences were analyzed by both human and RECall interpretation. RECall analysis required minimal hands-on time and resulted in a 25-fold improvement in processing speed (∼150 technician-hours versus ∼6 computation-hours). Excellent concordance was obtained between human and automated RECall interpretation (99.7% agreement for >1,000,000 bases compared). Nearly all discordances (99.4%) were due to nucleotide mixtures being called by one method but not the other. Similarly, 98.6% of key antiretroviral resistance-associated mutations observed were identified by both methods, resulting in 98.5% concordance of resistance susceptibility interpretations. This automated sequence analysis tool provides both standardization of analysis and a significant improvement in data workflow. The time-consuming, error-prone, and dreadfully boring manual sequence analysis step is replaced with a fully automated system without compromising the accuracy of reported HIV drug resistance data.
authors.affiliation: BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
authors.forename: Conan K
authors.initials: CK
authors.lastname: Woods
authors.forename: Chanson J
authors.initials: CJ
authors.lastname: Brumme
authors.forename: Tommy F
authors.initials: TF
authors.lastname: Liu
authors.forename: Celia K S
authors.initials: CK
authors.lastname: Chui
authors.forename: Anna L
authors.initials: AL
authors.lastname: Chu
authors.forename: Brian
authors.initials: B
authors.lastname: Wynhoven
authors.forename: Tom A
authors.initials: TA
authors.lastname: Hall
authors.forename: Christina
authors.initials: C
authors.lastname: Trevino
authors.forename: Robert W
authors.initials: RW
authors.lastname: Shafer
authors.forename: P Richard
authors.initials: PR
authors.lastname: Harrigan
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology; D001331:Automation / Q000379:methods*; D024882:Drug Resistance, Viral; D005838:Genotype; D015658:HIV Infections / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000592:standards; D058889:Molecular Typing / Q000379:methods*; D017421:Sequence Analysis / Q000379:methods; D013997:Time Factors; D014773:Virology / Q000379:methods* / Q000592:standards
chemical_list: D019380:Anti-HIV Agents